Patients at any hospital where we have a trial will not have to file an EIND to get leronlimab. As long as they meet study criteria they're in the no placebo extension study. Leronlimab would not get that unless the FDA has high confidence in the drug. It also means they won't have to deal with the EINDs they know they'll be getting from doctors who are already using the drug and know how good it is.